Olaparib in Patients With HRD Malignant Mesothelioma

Summary

In this study, researchers will give olaparib (a drug) to mesothelioma patients who have specific changes in their DNA (known as gene mutations). Researchers will give this drug to each patient on the study to find out if it will help the patient's tumor shrink or stop growing.

Timeline

Start

2021-02-19

Primary completion

2028-04-15

Completion

2028-04-15

Drugs

Indications